Harald Anderson (Former)
11 – 20 of 95
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer : A randomized clinical trial
(
- Contribution to journal › Article
- 2015
-
Mark
Cardiovascular disease in Adult Life after Childhood Cancer in Scandinavia: A population-based cohort study of 32,308 one-year survivors
(
- Contribution to journal › Article
-
Mark
The adult life after childhood cancer in scandinavia (ALiCCS) study: Design and characteristics.
(
- Contribution to journal › Article
-
Mark
Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.
(
- Contribution to journal › Article
- 2014
-
Mark
Adult Life after Childhood Cancer in Scandinavia: Diabetes mellitus following treatment for cancer in childhood.
(
- Contribution to journal › Article
-
Mark
Hospital contacts for endocrine disorders in Adult Life after Childhood Cancer in Scandinavia (ALiCCS): a population-based cohort study.
(
- Contribution to journal › Article
-
Mark
Effect of Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma in Situ: 20 Years Follow-Up in the Randomized SweDCIS Trial.
(
- Contribution to journal › Article
-
Mark
Increased cardio and cerebrovascular mortality in breast cancer patients treated with postmastectomy radiotherapy - 25 year follow-up of a randomised trial from the South Sweden Breast Cancer Group.
(
- Contribution to journal › Article
- 2013
-
Mark
Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications
(
- Contribution to journal › Article
-
Mark
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
(
- Contribution to journal › Article